Caligan Partners’s Anika Therapeutics ANIK Stock Holding History

Caligan Partners’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.8M	Hold	1,435,130	–	–	1.38%	21
2025 Q4	$13.8M	Hold	1,435,130	–	–	1.14%	17
2025 Q3	$13.5M	Hold	1,435,130	–	–	1.77%	12
2025 Q2	$15.2M	Hold	1,435,130	–	–	2.92%	9
2025 Q1	$21.6M	Hold	1,435,130	–	–	4.5%	8
2024 Q4	$23.6M	Hold	1,435,130	–	–	5.98%	5
2024 Q3	$35.4M	Sell	1,435,130 -863	-0.1%	-$22.4K	11.24%	5
2024 Q2	$36.4M	Hold	1,435,993	–	–	8.5%	3
2024 Q1	$36.5M	Buy	1,435,993 +354,633	+33%	+$8.58M	9.64%	3
2023 Q4	$24.5M	Hold	1,081,360	–	–	8.26%	3
2023 Q3	$20.1M	Buy	1,081,360 +361,069	+50%	+$7.49M	9.25%	5
2023 Q2	$18.7M	Buy	720,291 +5,000	+0.7%	+$134K	10.52%	2
2023 Q1	$20.5M	Buy	715,291 +123,616	+21%	+$3.68M	14.33%	2
2022 Q4	$17.5M	Buy	+591,675	New	+$16.8M	14.58%	2

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners's ANIK Position: Q1 2026 in Review

Caligan Partners held its Anika Therapeutics (ANIK) position steady in Q1 2026 at 1,435,130 shares worth $20.8M. The position accounts for 1.38% of the portfolio, ranked #21.

Caligan Partners first reported a position in ANIK in Q4 2022 and has held it in 14 quarters since. The position peaked at $36.5M in Q1 2024. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

Caligan Partners held 1,435,130 shares of Anika Therapeutics worth $20.8M as of Q1 2026.
Caligan Partners left its Anika Therapeutics share count unchanged in Q1 2026.
Anika Therapeutics made up 1.38% of Caligan Partners's portfolio in Q1 2026, its #21 holding.
Caligan Partners first reported a position in Anika Therapeutics in Q4 2022 and has held it in 14 quarters since.
Caligan Partners's Anika Therapeutics position peaked at $36.5M in Q1 2024.
130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.